John Radcliffe Hospital
Oxford, OX3 9DU, United Kingdom
NCT Number: NCT04942483
Wheezing is common in preschool children and affects quality of life. Although asthma treatments such as inhaled steroids (ICS), which reduce swelling (inflammation) in the airways are used in this age group, they are often ineffective. That is because only some preschool children have the type of inflammation (known as Type 2 inflammation) that responds to ICS, thus many children are being unnecessarily exposed to side effects. It is difficult diagnosing Type 2 inflammation through history and examination, thus other indicators are needed to ensure ICS are only given to children who will benefit. These indicators are commonly known as biomarkers, and we are trying to find out if they are useful. We want to measure three biomarkers, without changing children's treatment. The first is blood eosinophils. which can be measured using a finger prick sample (like the blood drop used for measuring sugar levels in diabetic children). The second is to determine if allergic sensitization is present to allergens that are breathed in; these will be house dust mite, grass pollen, tree pollen, cat and dog hair. The final biomarker is a molecule that is produced in the airways of preschool children with Type 2 inflammation, called nitric oxide (NO). This is easily obtained, by having children breathe through a mask and collecting their breath in a bag, measuring NO later on. The children will be followed up with monthly electronic questionnaires and 3-monthly visits (virtual or face-to-face) for a year to evaluate whether these markers individually or in combination relate to subsequent wheezing outcomes, and how acceptable the measurements are to families using a questionnaire and focus group approach. The results will form the basis of the design of a national trial of biomarker-driven therapy in such children.
Looking for future studies?
Notify Me1 year–5 year
All sexes
Observational
Oxford, OX3 9DU, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Peripheral blood eosinophil count will be measured from a finger prick blood sample, using the Haemocue machine, allowing a result in approximately 2 minutes. The test will allow to assess the presence or not of eosinophilia and if it can predict future wheezing exacerbations and response to inhaled corticosteroids (ICS).
Skin prick tests will be performed to: (a) house dust mite, (b) grass pollen, (c) tree pollen, (d) cat hair, (e) dog hair, as well as normal saline and histamine which will act as negative and positive controls respectively. In addition, skin prick tests will allow the assessment of which aeroallergen is the most useful predictor of outcomes in preschool children.
The child will breathe normally into a sample bag that will be collected for later analysis of FeNO levels. The test will be performed twice.
Time frame: 1-year follow-up
Defined as requiring an unscheduled healthcare visit to the ED or GP.
Time frame: 1 year follow-up period
Children unable to attend childcare facility due to a wheeze attack. There were no arms in this study, only a single group followed in an identical manner.
Time frame: 1 year follow-up period
Days out of work parents needed to take because of their child's wheeze attack. There were no arms in this study, only a single group followed in an identical manner.
Time frame: 12-months
The acceptability of the three biomarker tests by parents to be used in clinical practice was assessed through focus group discussions.
Imperial College London
Other
Biomarkers in Preschool Children With Wheeze to TArget Therapy wIth inhaLed cORticosteroids (TAILOR): a Feasibility Study".
Acronym: TAILOR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02148796
Asthma, Bronchial Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05064631
Bronchial Diseases, Bronchiolitis
London, United Kingdom
View Trial DetailsNCT06982911
Behavior, Cough
Diyarbakır, Turkey (Türkiye)
View Trial DetailsNCT03203603
Asthma, Bronchial Diseases
Indianapolis, Indiana, United States
View Trial Details